# JSI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jsi

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.jsinnopharm.com
- Latest round: Series B (Nov 15, 2021)
- Investors on record: 9

## About

Established in 2010 and based in Shanghai, China, JSI operates as a pharmaceutical R&D service provider that focuses on new small molecule anti-cancer drugs. Mr. Jintao Zhang once served as CEO and co-founder of Shanghai Medicilon Inc.

The company provides new small molecule anti-cancer drugs. The business of the company includes drug molecular design, drug synthesis and evaluation of biological activity in vitro and in vivo. The product of the company includes VIC-1911, JSI-1187 and E6201.

The company will increase investment in researching and developing core product.

## Funding rounds

- Series B, Nov 15, 2021 — Efung Capital, Baidu Ventures, Jiuyo Capital, Ming Bioventures, Tigermed, Shenzhen Qianhai Beizeng Asset Management
- Series A, Jun 15, 2020 — Oriental Fortune Capital, Suzhou International Development Venture Capital Holding, Efung Capital, Ming Bioventures
- Series A, Jan 1, 2019 — BioTrack Capital

## Investors

- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series A
- Suzhou International Development Venture Capital Holding (https://capitalatlas.ai/funds/suzhou-international-development-venture-capital-holding) — Series A
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series A, Series B
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series A, Series B
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series B
- Jiuyo Capital (https://capitalatlas.ai/funds/jiuyo-capital) — Series B
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series B
- Shenzhen Qianhai Beizeng Asset Management (https://capitalatlas.ai/funds/shenzhen-qianhai-beizeng-asset-management) — Series B